Hepatocellular carcinoma: systemic therapies and future perspectives

Area of Science:

• Hepatology
• Oncology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is the most common primary liver cancer globally.
• It ranks as the fifth most common solid cancer and third leading cause of cancer death worldwide.
• Current treatments offer limited survival benefits for unresectable HCC, necessitating advanced research.

Purpose of the Study:

• To review current systemic treatment options for HCC.
• To explore the molecular pathogenesis of HCC.
• To discuss future therapeutic directions, emphasizing immunotherapy and targeted therapies.

Main Methods:

• Literature review of systemic options for HCC.
• Analysis of molecular pathogenesis.
• Discussion of emerging immune-based and molecularly-targeted therapies.

Main Results:

• HCC incidence is projected to rise due to hepatitis C and obesity-related cirrhosis.
• Existing treatments have survival rates below 5% for unresectable cases.
• Novel therapeutic strategies are crucial for improving patient outcomes.

Conclusions:

• There is an urgent need for intensified research into HCC treatments.
• Future directions include immune-based and molecularly-targeted therapies.
• Advanced research is critical to combat the increasing burden of liver cancer.